Clinical Trials
50 trialsAMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
INTEGRAL
The Methodist Hospital Research Institute
neoMono
Palleos Healthcare GmbH
Olinvacimab With Pembrolizumab in Patients With mTNBC
PharmAbcine
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
University of Chicago
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Mayo Clinic
MK-2140-002
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
ELEVATE TNBC
Gilead Sciences
TNBC
Zenith Epigenetics
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
M.D. Anderson Cancer Center
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Sun Yat-sen University
PERSEVERE
Hoosier Cancer Research Network
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
Chipscreen Biosciences, Ltd.
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
G1 Therapeutics, Inc.
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
M.D. Anderson Cancer Center
Sitravatinib in Metastatic Breast Cancer
Baylor Breast Care Center
TENACITY
Ayala Pharmaceuticals, Inc,
TARA
Hoosier Cancer Research Network
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Barbara Ann Karmanos Cancer Institute
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
EMD Serono
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Washington University School of Medicine
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
University of Wisconsin, Madison
0927GCC
University of Maryland, Baltimore
DETECT
Shanghai Jiao Tong University School of Medicine
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics, Inc.
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
University of Wisconsin, Madison
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
BerGenBio ASA
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
Swiss Cancer Institute
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Sanofi
A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer
University of Wisconsin, Madison
CONTESSA TRIO
Odonate Therapeutics, Inc.
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Sun Yat-sen University
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer
Sun Yat-sen University
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
GTx
BATON-BC
AVEO Pharmaceuticals, Inc.
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Virginia Commonwealth University
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Effector Therapeutics
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Pfizer
VICTOR3
Mario Negri Institute for Pharmacological Research
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
Wake Forest University Health Sciences
Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Fudan University
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
National Cancer Institute (NCI)
META2
Centre Jean Perrin
Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer
European Institute of Oncology
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Emory University